Company

Recce Pharmaceuticals Ltd

ASX:RCE

Recce Pharmaceuticals Ltd (ASX:RCE) is developing a new class of synthetic anti-infectives designed to address the urgent global health threat of antibiotic-resistant superbugs.

169 stories · page 6 of 9

Pharma & Biotech

Recce Pharmaceuticals welcomes positive case studies and research data for R327 gel formulation; shares up

By Proactive 08/08/2023

Pharma & Biotech

Recce Pharmaceuticals awarded Australian patent for lead anti-infectives

By Proactive 04/08/2023

Pharma & Biotech

Recce Pharmaceuticals’ advances RECCE® 327 development ; completes UTI trials ahead of schedule

By Proactive 28/07/2023

Pharma & Biotech

Recce Pharmaceuticals to present abstract on antimicrobial countermeasures for wound infections in military personnel at MHSRS

By Proactive 27/07/2023

Pharma & Biotech

Recce Pharmaceuticals begins Phase I/II UTI clinical trial ahead of schedule

By Proactive 24/07/2023

Pharma & Biotech

Recce Pharmaceuticals verifies positive Phase 1 data from R327 intravenous study

By Proactive 19/07/2023

Pharma & Biotech

Recce Pharmaceuticals’ valuation lifted by Edison Investment Research following progress on RECCE 327

By Proactive 12/07/2023

Pharma & Biotech

Recce Pharmaceuticals receives A$801,604 in R&D rebate advance

By Proactive 12/07/2023

Pharma & Biotech

Recce Pharmaceuticals doses first cohort in RECCE 327 rapid infusion phase I/II UTI clinical trial

By Proactive 10/07/2023

Pharma & Biotech

Recce Pharmaceuticals receives Ethics Approval to expand R327 Faster Infusion, Phase I/II Clinical Trial

By Proactive 29/06/2023

Pharma & Biotech

Recce Pharmaceuticals recruits outpatient nurses to drive “largest in Australia” diabetic foot infection clinical trial

By Proactive 29/05/2023

Pharma & Biotech

Recce Pharmaceuticals gains WA government support for BIO Korea 2023

By Proactive 08/05/2023

Pharma & Biotech

Recce Pharmaceuticals has ethics approval to move to Phase 1/2 IV trial of anti-infective for UTIs

By Proactive 17/04/2023

Pharma & Biotech

FIVE at FIVE AU: ASX sets new 20-day high; Tiger GPT brings generative AI to the market; pro-Russian KillNet targets NATO

By Proactive 12/04/2023

Pharma & Biotech

Recce Pharmaceuticals registers RECCE® trademark at Israeli Patent Office

By Proactive 12/04/2023

Pharma & Biotech

Recce Pharmaceuticals welcomes ‘intent to grant’ Family 4 patent for anti-infectives

By Proactive 11/04/2023

Pharma & Biotech

Recce Pharmaceuticals receives further A$973,144 in R&D advance

By Proactive 04/04/2023

Pharma & Biotech

Recce Pharmaceuticals receives $A2.79 valuation from Edison Investment Research

By Proactive 09/03/2023

Pharma & Biotech

The smart money in medicine: the silent pandemic

When antibiotics – which have underwritten our way of life for the last 100 years – are no longer effective, mundane medical procedures will become almost impossibly risky.

By Proactive 01/03/2023

Pharma & Biotech

Recce Pharmaceuticals selects CMAX research facility for Phase 1/2 urinary tract infection clinical trial

By Proactive 20/02/2023